Medivation Inc., of San Francisco, said U.S. net sales of Xtandi (enzalutamide) capsules, as earlier disclosed by partner Astellas Pharma Inc., of Tokyo, were $230.2 million for the quarter (up 82 percent vs. prior year) and $679.8 million for the full year 2014 (up 73 percent vs. prior year).